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Fig. 1. Fold change expression levels of inﬂammatory mediators and
adipokines measured infrapatellar fat pad after idealized ACL recon-
struction in a sheep knee. Levels are normalized to 18S rRNA.
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S289treatment of siNeg. (Fig. A) Paw swelling was signiﬁcantly reduced 16–28
days after immunization, which was not observed in the siNeg group.
(Fig. B) Histological examination of the paws of siCx43-treated rats was
virtually normal histologically, and their cartilage and bone remained
almost unaffected. (Fig. C) Histological arthritis scoring also indicated that
the manifestations of arthritis were signiﬁcantly milder in rats treated
with siCx43 than in siNeg-treated rats.
Conclusions: We showed, in the past meeting, that lipopolysaccharide
(LPS)-stimulation of rat FLS increased the expression of Cx43, and that
transfection of siCx43 inhibited the expression of LPS-induced TNF-a,
IL-6, and IL-1b mRNA and protein in vitro. In this study, intra-articular
injection of siCx43 signiﬁcantly reduced joint inﬂammation in arthritis
model. These ﬁndings suggest that Cx43 may be a novel regulator of
inﬂammation in the synovium of arthritis, and that siCx43 may have
therapeutic effects of arthritis through suppression of pro-inﬂamma-
tory cytokines.
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IL-36a: A NOVEL CYTOKINE INVOLVED IN THE INFLAMMATORY
RESPONSE IN HUMAN CHONDROCYTES
J. Conde y, M. Scotece y, V. Abella y,z, V. Lopez y, V. Lazzaro y,x, J. Pino y,
J.J. Gomez-Reino y, O. Gualillo y. y SERGAS-IDIS Santiago Univ. Clinical
Hosp., Santiago de Compostela, Spain; zUniv. of A Coru~na, A Coru~na,
Spain; xUniversita della Magna Grecia, Catanzaro, Italy
Purpose: Recently, a novel member of the IL-1 family has been iden-
tiﬁed. IL-36a (also termed IL-1F6) is a 17 kDa protein that binds to a
heterodimeric receptor composed by the IL-36 receptor (IL-36R) sub-
unit and the IL-1 receptor accessory protein (IL-1RAcP). Several studies
confer to IL-36a pro-inﬂammatory properties and suggest that this
cytokine contributes to synovial inﬂammation in psoriatic arthritis,
rheumatoid arthritis and osteoarthritis. However, little is known about
the expression and function of IL-36a in cartilage. Then, the aim of this
study is to describe the expression of IL-36a in chondrocytes, the
potential modulation of this cytokine by classic pro-inﬂammatory
mediators and the effects of IL-36a on inﬂammation, chemotaxis and
catabolism in human chondrocytes.
Methods:We ﬁrst analyzed mRNA and protein expression of IL-36a by
RT-qPCR and western blot in human primary chondrocytes. We also
tested the expression of different markers of inﬂammation, chemotaxis
and catabolism in IL-36a-treated human chondrocytes by RT-qPCR. The
IL-36a receptor signal transduction pathway, upon IL-36a stimulation
was also explored by western blot analysis in human primary
chondrocytes.
Results: We detect low basal expression of IL-36a mRNA in human
chondrocytes. Moreover, IL-36a mRNA levels were not modulated
neither by IL-1 nor by TNF-a. However, human primary chondrocytes
express IL-36a receptor, suggesting potential paracrine effects. Actually,
we observed a signiﬁcant increase in IL-6, IL-8 and MMP-13 in IL-36a-
treated human chondrocytes. Finally, we observed that upon IL-36a
treatment, MAPKs and NF-kB were also altered.
Conclusions: Here we demonstrate that human chondrocytes express
low endogenous levels of IL-36a mRNA being not modulated by IL-1 or
TNF-a. The fact that human chondrocytes express functional receptors,
whose activation leads to increase of pro-inﬂammatory mediators,
suggested a potential role of this novel member of the cytokine
superfamily in the pathophysiology of articular chondrocytes.
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INJURY INDUCED INFLAMMATION HAS DISTINCT EFFECTS ON
ADIPOKINE EXPRESSION LEVELS IN THE INFRAPATELLAR FAT PAD
AFTER IDEALIZED ANTERIOR CRUCIATE LIGAMENT
RECONSTRUCTION
N.M. Solbak, Y. Achari, M. Chung, B.J. Heard, N.G. Shrive, C.B. Frank,
D.A. Hart. Univ. of Calgary, Calgary, AB, Canada
Purpose: The infrapatellar fat pad (IPFP) is located between the patellar
tendon and anterior tibial plateau of the knee. Removal of this tissue
during arthoplasty often results in persistant anterior joint pain. The
structure is a repository of inﬂammatory mediators which leads to joint
pain, swelling and stiffness. These symptoms are associated in the
development of osteoarthritis (OA). Although OA is primarily associated
with the destruction of cartilage, all components of the knee joint may
contribute to the development of OA. Development of secondary OAoften arises if injuries to the anterior cruciate ligament (ACL) are left
untreated. The current gold standard treatment involves surgical
reconstruction of the ACL. Clinical studies have documented ﬁbrosis,
extending into tissues adjacent to the patellar tendon such as the IPFP
thus leading to knee locking and anterior knee pain and eventual
development of OA. We have investigated joint changes following an
anatomically (& biomechanically nearly ‘perfect’) ACL autograft (ACL-R)
in an ovine model and still observed evidence for early joint degener-
ation in the ACL-R sheep stiﬂe joints. Previous studies have suggested
that the production of systemic inﬂammatory mediators called adipo-
kines from IPFP may exert some pro-inﬂammatory and pro-catabolic
actions on cartilage. The present study was based on the hypothesis the
IPFP will contribute to the development and/or progression of joint
degeneration through production of pro-inﬂammatory adipokines and
enhanced ﬁbrosis even after idealized ACL-R surgery.
Methods: 21 skeletally mature (age ¼ 3-4years) female Suffolk-cross
sheep were allocated to three groups: Control (n ¼ 5), 2 weeks post
ACL-R (n ¼ 9) and 20 weeks post ACL-R (n ¼ 7). IPFP tissue samples
from operated stiﬂe knee joints were harvested and frozen for his-
tological processing. Sections were cut and stained following
standard Haematoxylin and Eosin (H&E) staining procedures. Sec-
ondly, parts of these tissues were also assessed by real time q-PCR
for mRNA levels of select inﬂammatory mediators: Interleukin (IL)-
1b, IL-8, leptin, visfatin and adiponectin. The mRNA expression levels
were normalized to 18S mRNA. ANOVA with Bonferroni post-hoc
analysis was used to determined differences in expression levels
between groups, using SPSS 19.0.
Results: Expression levels of IL-1b and IL-8 were signiﬁcantly
upregulated at 2 weeks post ACL-R (p ¼ 0.05 and p < 0.001,
respectively). Expression of leptin was signiﬁcantly down-regulated
at the 2 and 20 week timepoints (p < 0.001 and p ¼ 0.004,
respectively). Visfatin expression was signiﬁcantly increased at 2
weeks (p ¼ 0.018). Adiponectin did not change from time of
reconstruction to 2 weeks, but was signiﬁcantly decreased at 20
weeks compared to 2-week expression levels (p ¼ 0.044). Histo-
logically, IPFP at 2 weeks showed enhanced cellularity, vascularity
and ﬁbrosis compared to controls. Furthermore, this observation was
observed at the 20-week time point. Gross morphology scores were
signiﬁcantly higher at 20 weeks. This correlated with expression
levels of IL-1b in the IPFP. No adipokines showed any signiﬁcant
association with the gross morphology score.
Conclusions: After ACL-R, inﬂammation was present by 2 weeks post
surgery in the IPFP. The mRNA levels of interleukins at 2 weeks in IPFP is
similar to that previously reported for synovium in the same model. At
20 weeks, inﬂammatory mediator expression was lowered but ﬁbrosis
in the tissue was still evident. The mRNA levels varied for speciﬁc adi-
pokines such as visfatin, leptin and adiponectin found in the IPFP. The
distinctive response to injury-induced inﬂammation suggests there is a
modiﬁed function of the IPFP that is dependent on the adipokine
involved. The down-regulation of leptin at both timepoints post-injury
may indicate a regulatory function of leptin in the IPFP and this may
contribute to the long-term post-operative development of OA after
ACL-R.X – represents the moan expression level for each group and marker
shown
B, Δ - represent a single measure from each sample in the group
# - Signiﬁcant difference between Control and 2 w expression levels
& - Signiﬁcant difference between 2 w and 20 weeks
@ - Signiﬁcant difference between Control and 20 weeks
